Everpar Advisors LLC Takes $296,000 Position in Zoetis Inc. (NYSE:ZTS)

Everpar Advisors LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,499 shares of the company’s stock, valued at approximately $296,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Gryphon Financial Partners LLC raised its holdings in Zoetis by 11.8% in the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after purchasing an additional 322 shares during the period. Sawgrass Asset Management LLC grew its position in shares of Zoetis by 28.1% in the fourth quarter. Sawgrass Asset Management LLC now owns 55,827 shares of the company’s stock valued at $11,019,000 after purchasing an additional 12,242 shares in the last quarter. Peddock Capital Advisors LLC grew its position in shares of Zoetis by 10.0% in the fourth quarter. Peddock Capital Advisors LLC now owns 5,938 shares of the company’s stock valued at $1,172,000 after purchasing an additional 540 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in Zoetis by 16.8% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 1,855 shares of the company’s stock valued at $366,000 after acquiring an additional 267 shares during the last quarter. Finally, Apollon Wealth Management LLC lifted its holdings in Zoetis by 25.5% in the fourth quarter. Apollon Wealth Management LLC now owns 12,515 shares of the company’s stock valued at $2,470,000 after acquiring an additional 2,541 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now directly owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 2,209 shares of company stock worth $371,293. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS traded down $3.53 during mid-day trading on Wednesday, reaching $164.92. The stock had a trading volume of 4,669,191 shares, compared to its average volume of 3,195,939. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The firm has a market capitalization of $75.25 billion, a price-to-earnings ratio of 31.78, a PEG ratio of 2.57 and a beta of 0.86. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The business has a 50 day simple moving average of $167.64 and a 200 day simple moving average of $178.93.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter last year, the firm earned $1.31 earnings per share. The firm’s revenue was up 9.5% compared to the same quarter last year. On average, analysts expect that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ZTS. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. HSBC dropped their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday. The Goldman Sachs Group dropped their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday. Finally, Barclays dropped their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.